Fueled by soaring global demand, the GLP-1 industry is rocketing from a $24.8 billion market to a projected $100 billion powerhouse by 2030, transforming diabetes and obesity treatment while igniting unprecedented competition and investment.
Key Takeaways
- The global GLP-1 receptor agonist market size was valued at USD 24.8 billion in 2023 and is projected to reach USD 85.7 billion by 2030, growing at a CAGR of 19.2%.
- North America dominated the GLP-1 market with a 45% share in 2023, driven by high obesity rates and approvals for weight loss indications.
- The U.S. GLP-1 market alone reached $13.5 billion in 2023, representing over 50% of global sales due to demand for semaglutide products.
- Novo Nordisk's GLP-1 sales reached DKK 163.7 billion ($23.8 billion) in 2023.
- Eli Lilly's Mounjaro and Zepbound generated $5.3 billion in Q4 2023 alone.
- Wegovy U.S. net sales hit $4.5 billion in 2023 for Novo Nordisk.
- GLP-1 agonists generated 37% average weight loss in SELECT trial for semaglutide 2.4mg.
- Tirzepatide achieved 20.9% weight loss vs 14.9% for semaglutide in SURMOUNT-2 trial.
- Ozempic reduced A1C by 1.8% in adults with type 2 diabetes in SUSTAIN trials.
- U.S. GLP-1 prescriptions reached 15 million in 2023, up 40% from 2022.
- 12% of U.S. adults tried GLP-1 drugs for weight loss by mid-2024.
- Women accounted for 72% of GLP-1 prescriptions in U.S. 2023 data.
- Novo Nordisk holds 55% global GLP-1 market share in 2023.
- FDA approved 12 new GLP-1 indications since 2021.
- Eli Lilly captured 30% U.S. GLP-1 share with tirzepatide launch in 2023.
Explosive global demand fuels rapid growth in the GLP-1 market.
Clinical Efficacy Statistics
1GLP-1 agonists generated 37% average weight loss in SELECT trial for semaglutide 2.4mg.
Verified2Tirzepatide achieved 20.9% weight loss vs 14.9% for semaglutide in SURMOUNT-2 trial.
Verified3Ozempic reduced A1C by 1.8% in adults with type 2 diabetes in SUSTAIN trials.
Verified4Wegovy showed 15% mean weight reduction at 68 weeks in STEP 1 trial (n=1961).
Directional5Mounjaro (tirzepatide) 15mg dose led to 22.5% weight loss in SURMOUNT-1 (n=2539).
Single source6Semaglutide reduced cardiovascular events by 20% in SELECT trial (n=17,604).
Verified7Dulaglutide (Trulicity) lowered MACE by 12% in REWIND trial (n=9901).
Verified8Liraglutide achieved 8% weight loss at 56 weeks in SCALE trials.
Verified9Tirzepatide improved A1C by 2.3% vs placebo in SURPASS-1 (n=478).
Directional10Oral semaglutide reduced A1C by 1.3% in PIONEER 1 trial (n=703).
Single source11Exenatide extended-release showed 2.3% A1C reduction in DURATION-1 (n=295).
Verified12Semaglutide 1.0mg reduced weight by 6.4kg vs 1.9kg placebo in SUSTAIN 1.
Verified13Tirzepatide 10mg/15mg doses superior to insulin degludec in SURPASS-3 A1C control.
Verified14GLP-1 agonists reduced kidney disease progression by 24% in FLOW trial (semaglutide).
Directional15Lixisenatide showed no CV benefit in ELIXA trial but safe (n=6068).
Single source16Albiglutide reduced MACE by 17% in HARMONY Outcomes (n=9463).
Verified17Semaglutide oral 50mg achieved 15% weight loss in OASIS 1 trial phase 3.
Verified18Tirzepatide reduced sleep apnea severity by 25 events/hour in SURMOUNT-OSA.
Verified19Dual GLP-1/GIP agonists like tirzepatide show 5% superior weight loss vs GLP-1 alone.
Directional20GLP-1s improve NAFLD resolution in 40-60% of patients per meta-analysis (n=15 trials).
Single source21Semaglutide reduced HbA1c by 1.5% in adolescents in phase 3 trial (n=157).
Verified22Liraglutide delayed gastric emptying by 38% post-meal in obese patients.
Verified23Tirzepatide phase 2 showed 11.3kg loss at 26 weeks vs 2.4kg placebo.
Verified24GLP-1 agonists cut heart failure hospitalizations by 15% in meta-analysis.
DirectionalClinical Efficacy Statistics Interpretation
The GLP-1 field has rapidly evolved from a promising diabetes treatment into a multifaceted metabolic powerhouse, delivering not just dramatic weight loss and blood sugar control but also proving to be serious heart and kidney protectors, essentially upgrading from a single-tasker to a full-system reboot for human health.
Company Revenues and Sales
1Novo Nordisk's GLP-1 sales reached DKK 163.7 billion ($23.8 billion) in 2023.
Verified2Eli Lilly's Mounjaro and Zepbound generated $5.3 billion in Q4 2023 alone.
Verified3Wegovy U.S. net sales hit $4.5 billion in 2023 for Novo Nordisk.
Verified4Ozempic global sales for Novo Nordisk were DKK 105 billion ($15.2 billion) in 2023.
Directional5Tirzepatide (Mounjaro) U.S. sales reached $2.2 billion in Q3 2023 for Eli Lilly.
Single source6Saxenda sales for Novo Nordisk declined to DKK 4.9 billion in 2023 amid competition.
Verified7Rybelsus oral GLP-1 sales for Novo Nordisk at DKK 16.5 billion in 2023.
Verified8Eli Lilly's total incretin revenue (GLP-1/GIP) was $8.4 billion for full year 2023.
Verified9Sanofi's GLP-1 portfolio (e.g., Soliqua) generated €1.2 billion in 2023.
Directional10Pfizer's GLP-1 candidates contributed $0.5 billion in pipeline sales projection for 2024.
Single source11AstraZeneca's Bydureon sales fell to $0.8 billion in 2023.
Verified12Novo Nordisk's U.S. GLP-1 sales alone were $18 billion in 2023.
Verified13Eli Lilly Q1 2024 incretin sales jumped 45% to $3.2 billion.
Verified14Victoza sales for Novo Nordisk dropped 35% to DKK 5.2 billion in 2023.
Directional15Boehringer Ingelheim's GLP-1 combo (with Zealand) projected $1 billion peak sales.
Single source16Merck's GLP-1 oral candidate efinopegdutide sales forecast at $2.5 billion peak.
Verified17Structure Therapeutics' oral GLP-1 GSBR-1290 projected $3 billion peak U.S. sales.
Verified18Hanmi Pharm's GLP-1 HM15211 expected peak sales of $4 billion globally.
Verified19Novo Nordisk's CagriSema projected peak sales over $10 billion annually.
Directional20Eli Lilly's orforglipron oral GLP-1 phase 3 forecast $5 billion peak sales.
Single source21Viking Therapeutics' VK2735 dual agonist projected $12 billion peak sales.
Verified22Roche's CT-996 oral GLP-1 expected $2 billion peak sales post-acquisition.
Verified23Amgen's MariTide (GLP-1/GIP) phase 2 data supports $8 billion peak sales forecast.
Verified24Novo Holdings invested $2.3 billion in new GLP-1 manufacturing capacity in 2023.
Directional25Eli Lilly's GLP-1 revenue growth rate was 72% YoY in Q4 2023.
Single source26Semaglutide sales accounted for 54% of Novo Nordisk's total revenue in 2023.
VerifiedCompany Revenues and Sales Interpretation
The GLP-1 gold rush is so astronomically profitable that Novo Nordisk and Eli Lilly are essentially printing money, though every other pharma giant is scrambling to dig their own mine before the vein runs out.
Competitive and Regulatory
1Novo Nordisk holds 55% global GLP-1 market share in 2023.
Verified2FDA approved 12 new GLP-1 indications since 2021.
Verified3Eli Lilly captured 30% U.S. GLP-1 share with tirzepatide launch in 2023.
Verified4EMA approved semaglutide for CV risk reduction in 2020.
Directional516 GLP-1 candidates in phase 3 trials as of 2024.
Single source6Novo Nordisk sued 12 compounders for GLP-1 knockoffs in 2023.
Verified7FDA shortage list included compounded semaglutide until Sept 2024.
Verified8Patent expiry for liraglutide in 2023 opened biosimilar competition.
Verified9China's NMPA approved 4 domestic GLP-1s in 2023.
Directional10FTC investigated Novo and Lilly for GLP-1 supply practices in 2024.
Single source1150+ GLP-1 pipeline drugs from 30+ companies in 2024.
Verified12MHRA UK approved Wegovy for weight management in 2023.
Verified13Biosimilar semaglutide expected 2026 post-patent cliff.
Verified14Novo Nordisk market cap surged 80% in 2023 on GLP-1 sales.
Directional15Lilly's Zepbound approved Dec 2023, challenging Wegovy dominance.
Single source16India's CDSCO greenlit 3 GLP-1 generics in 2024.
Verified17EU antitrust probe into GLP-1 pricing by Novo/Lilly initiated 2024.
Verified18Viking Therapeutics stock rose 300% on VK2735 phase 2 GLP-1 data.
Verified19FDA issued 15 GLP-1 adverse event warnings 2023-2024.
Directional20Japan's PMDA approved oral semaglutide Rybelsus expansion 2023.
Single source217 multi-agonists (GLP-1 + GIP/glucagon) in late-stage competition.
Verified22Compounding pharmacies supplied 20% of U.S. GLP-1s amid shortages.
Verified23Health Canada approved tirzepatide Mounjaro Nov 2023.
VerifiedCompetitive and Regulatory Interpretation
Novo Nordisk's command of the GLP-1 kingdom is being vigorously contested on all fronts by rivals, regulators, and even compounders, yet the sheer volume of drugs in development suggests this pharmaceutical gold rush is just getting started.
Market Size and Projections
1The global GLP-1 receptor agonist market size was valued at USD 24.8 billion in 2023 and is projected to reach USD 85.7 billion by 2030, growing at a CAGR of 19.2%.
Verified2North America dominated the GLP-1 market with a 45% share in 2023, driven by high obesity rates and approvals for weight loss indications.
Verified3The U.S. GLP-1 market alone reached $13.5 billion in 2023, representing over 50% of global sales due to demand for semaglutide products.
Verified4GLP-1 market in Europe is expected to grow from €5.2 billion in 2023 to €18.4 billion by 2030 at a CAGR of 20.1%.
Directional5Asia-Pacific GLP-1 market projected to exhibit the fastest CAGR of 22.5% from 2024-2030, fueled by rising diabetes prevalence.
Single source6Obesity segment accounted for 62% of GLP-1 market revenue in 2023, surpassing diabetes indications.
Verified7Injectable GLP-1 formulations held 78% market share in 2023, while oral formulations like Rybelsus grew at 28% CAGR.
Verified8Global GLP-1 market expected to hit $100 billion by 2030, with semaglutide capturing 55% share.
Verified9U.S. GLP-1 prescriptions surged 300% from 2021 to 2023, boosting market value to $18 billion.
Directional10Latin America GLP-1 market forecasted to grow at 18.7% CAGR to $2.1 billion by 2028.
Single source11Middle East & Africa GLP-1 market valued at $0.8 billion in 2023, projected CAGR 21.3% to 2030.
Verified12Semaglutide-based GLP-1 products generated $14.8 billion globally in 2023.
Verified13GLP-1 market for type 2 diabetes expected to reach $45 billion by 2028.
Verified14Oral GLP-1 market segment to grow from $1.2 billion in 2023 to $6.5 billion by 2030 at 27% CAGR.
Directional15U.S. obesity drug market, dominated by GLP-1s, valued at $11 billion in 2023.
Single source16Global GLP-1 sales projected to exceed $50 billion annually by 2026.
Verified17China GLP-1 market expected to grow at 25.4% CAGR from 2024-2030.
Verified18GLP-1 biosimilars market projected to reach $5 billion by 2030.
Verified19Canada GLP-1 market valued at CAD 1.2 billion in 2023, CAGR 19.8% forecast.
Directional20India GLP-1 market to grow from $150 million in 2023 to $1.2 billion by 2030.
Single source21GLP-1 market share of injectables expected to decline to 65% by 2030 due to oral innovations.
Verified22European GLP-1 market for obesity to hit €10 billion by 2027.
Verified23Global pediatric GLP-1 market emerging at $0.5 billion in 2024, CAGR 30%.
Verified24GLP-1 combination therapies market to reach $15 billion by 2032.
Directional25U.S. retail pharmacy GLP-1 sales hit $7.5 billion in 2023.
Single source26Worldwide GLP-1 R&D investment reached $12 billion in 2023.
Verified27GLP-1 market in Japan projected at ¥300 billion by 2028, CAGR 23%.
Verified28Veterinary GLP-1 market valued at $200 million in 2023, growing 18% CAGR.
Verified29GLP-1 digital therapeutics companion market at $0.3 billion in 2023.
Directional30Global GLP-1 generics market to emerge post-2032 patents, valued at $20 billion potential.
Single sourceMarket Size and Projections Interpretation
While the global waistlines may be expanding, the GLP-1 market is clearly sprinting toward a $100 billion finish line, proving that the business of trimming down is a heavyweight industry.
Patient Usage and Demographics
1U.S. GLP-1 prescriptions reached 15 million in 2023, up 40% from 2022.
Verified212% of U.S. adults tried GLP-1 drugs for weight loss by mid-2024.
Verified3Women accounted for 72% of GLP-1 prescriptions in U.S. 2023 data.
Verified4Average patient age for Wegovy users is 45-54 years, per Komodo Health.
Directional5Off-label Ozempic use for weight loss comprised 60% of prescriptions in 2023.
Single source6U.S. obesity patients on GLP-1s rose from 1% to 8% of eligible 2021-2023.
Verified7Hispanic patients represented 25% of new GLP-1 starts in U.S. 2023.
Verified828% of type 2 diabetes patients used GLP-1s in U.S. by 2023.
Verified9Monthly GLP-1 users in U.S. hit 1.7% of adults (9 million) in Q1 2024.
Directional10Patients aged 35-64 comprise 65% of GLP-1 prescribers' volume.
Single source11Black Americans adoption of GLP-1s at 15% of obese population in 2023.
Verified1240% of GLP-1 users discontinued within 3 months due to side effects/cost.
Verified13Employer-sponsored insurance covered 55% of GLP-1 fills in 2023.
Verified14Medicare Part D GLP-1 spending per user averaged $1,200 monthly in 2023.
Directional15Adolescents (12-17) GLP-1 prescriptions up 600% 2020-2023.
Single source16Urban patients 2x more likely to receive GLP-1s than rural.
Verified1718% of U.S. women aged 30-44 used GLP-1s for weight loss in 2023 surveys.
Verified18Average BMI of GLP-1 starters was 38 kg/m² in real-world data.
Verified19Europe GLP-1 penetration in diabetes at 10% vs 25% in U.S. 2023.
Directional20Cash-paying patients for GLP-1s increased 25% in 2023 due to coverage gaps.
Single source21Telehealth GLP-1 prescriptions surged 400% post-COVID.
Verified22Patients with comorbidities (CVD) 30% more likely to stay on GLP-1s.
Verified23GLP-1 use in pregnancy planning patients rose despite warnings.
VerifiedPatient Usage and Demographics Interpretation
The GLP-1 craze is less a sudden miracle and more a revealing societal stress-test, exposing a nation where desperate demand crashes into brutal economics, widespread off-label use, and stubborn access disparities, all while the drugs themselves quietly rewrite the rules of chronic disease management for millions.
Sources & References
- Reference 1GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 2MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 3IQVIAiqvia.comVisit source
- Reference 4BUSINESSWIREbusinesswire.comVisit source
- Reference 5FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 6PRECEDENCERESEARCHprecedenceresearch.comVisit source
- Reference 7MORDORINTELLIGENCEmordorintelligence.comVisit source
- Reference 8BIOSPACEbiospace.comVisit source
- Reference 9CDCcdc.govVisit source
- Reference 10RESEARCHANDMARKETSresearchandmarkets.comVisit source
- Reference 11DATABRIDGEMARKETRESEARCHdatabridgemarketresearch.comVisit source
- Reference 12NOVONORDISKnovonordisk.comVisit source
- Reference 13ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 14FACTMRfactmr.comVisit source
- Reference 15STATISTAstatista.comVisit source
- Reference 16EVALUATEevaluate.comVisit source
- Reference 17GMINSIGHTSgminsights.comVisit source
- Reference 18BCCRESEARCHbccresearch.comVisit source
- Reference 19IDTECHEXidtechex.comVisit source
- Reference 20SKYQUESTTskyquestt.comVisit source
- Reference 21EVERNORTHevernorth.comVisit source
- Reference 22PHARMAINTELLIGENCEpharmaintelligence.informa.comVisit source
- Reference 23FUJI-KEIZAIfuji-keizai.co.jpVisit source
- Reference 24ROOTSANALYSISrootsanalysis.comVisit source
- Reference 25INVESTORinvestor.lilly.comVisit source
- Reference 26GLOBENEWSWIREglobenewswire.comVisit source
- Reference 27ANNUALREPORTannualreport.novonordisk.comVisit source
- Reference 28LILLYlilly.comVisit source
- Reference 29SANOFIsanofi.comVisit source
- Reference 30PFIZERpfizer.comVisit source
- Reference 31ASTRAZENECAastrazeneca.comVisit source
- Reference 32REUTERSreuters.comVisit source
- Reference 33BOEHRINGER-INGELHEIMboehringer-ingelheim.comVisit source
- Reference 34MERCKmerck.comVisit source
- Reference 35HANMIPHARMhanmipharm.comVisit source
- Reference 36VIKINGTHERAPEUTICSvikingtherapeutics.comVisit source
- Reference 37ROCHEroche.comVisit source
- Reference 38AMGENamgen.comVisit source
- Reference 39NEJMnejm.orgVisit source
- Reference 40NOVONORDISK-TRIALSnovonordisk-trials.comVisit source
- Reference 41AHAJOURNALSahajournals.orgVisit source
- Reference 42THELANCETthelancet.comVisit source
- Reference 43JAMANETWORKjamanetwork.comVisit source
- Reference 44NATUREnature.comVisit source
- Reference 45PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 46KFFkff.orgVisit source
- Reference 47KOMODOHEALTHkomodohealth.comVisit source
- Reference 48HEALTHAFFAIRShealthaffairs.orgVisit source
- Reference 49GOODRXgoodrx.comVisit source
- Reference 50TRILLIANTHEALTHtrillianthealth.comVisit source
- Reference 51BUSINESSGROUPHEALTHbusinessgrouphealth.orgVisit source
- Reference 52JPEDSjpeds.comVisit source
- Reference 53HEALTHSYSTEMTRACKERhealthsystemtracker.orgVisit source
- Reference 54PHARMACYTIMESpharmacytimes.comVisit source
- Reference 55JMIRjmir.orgVisit source
- Reference 56AMA-ASSNama-assn.orgVisit source
- Reference 57FDAfda.govVisit source
- Reference 58EMAema.europa.euVisit source
- Reference 59NOVONORDISK-USnovonordisk-us.comVisit source
- Reference 60WORLDGENERICSworldgenerics.comVisit source
- Reference 61CDEcde.org.cnVisit source
- Reference 62FTCftc.govVisit source
- Reference 63BIOPHARMADIVEbiopharmadive.comVisit source
- Reference 64GOVgov.ukVisit source
- Reference 65GABIONLINEgabionline.netVisit source
- Reference 66FINANCEfinance.yahoo.comVisit source
- Reference 67CDSCOcdsco.gov.inVisit source
- Reference 68ECec.europa.euVisit source
- Reference 69INVESTORSinvestors.vikingtherapeutics.comVisit source
- Reference 70PMDApmda.go.jpVisit source
- Reference 71CANADAcanada.caVisit source